Kejal Parikh

Trends in overall survival and costs of multiple myeloma, 2000–2014

Rafaël Fonseca, Safiya Abouzaid, Machaon Bonafede et al. · Leukemia · 2016 · 330 citations · Full text

Medicine, Oncology, Pharmacoeconomics +12

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis

Sikander Ailawadhi, Kejal Parikh, Safiya Abouzaid et al. · Blood Advances · 2019 · 127 citations · Full text

Medicine, Hematology, Oncology +13

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

Jipan Xie, M. Namjoshi, Eric Q. Wu et al. · Journal of Managed Care Pharmacy · 2011 · 58 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

James Signorovitch, Eric Q. Wu, Keith A. Betts et al. · Current Medical Research and Opinion · 2011 · 54 citations

Medicine, Hematology, Pharmacology +12

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

C. Pelligra, Kejal Parikh, Shien Guo et al. · Clinical Therapeutics · 2017 · 46 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17